Streetbeat News

Products Services

IVVD

The FDA granted emergency use authorization to Invivyd Inc's Pemgarda for COVID-19 prevention in individuals with immune compromise. Invivyd announced financial details, including a cash runway into Q4 2024, and shared interim data from the CANOPY Phase 3 trial of VYD222 (Pemgarda), showing promising results against COVID-19. However, IVVD shares dropped 13.20% to $3.79.

Portfolio Pulse from Vandana Singh

March 25, 2024 | 1:44 pm

CRWD

CrowdStrike (NASDAQ:CRWD) and HCLTech (NSE: HCLTECH) have announced a strategic partnership where HCLTech's managed detection and response (MDR) solutions will utilize CrowdStrike's AI-native Falcon XDR platform. This collaboration aims to enhance enterprise cybersecurity transformation, leveraging the Falcon platform's capabilities across various cybersecurity domains. The partnership is expected to address the increasing sophistication of cyberattacks and the cybersecurity skills gap by combining HCLTech's MDR expertise with CrowdStrike's technology.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:30 pm

BOSC

BOS Better Online Solutions Ltd. (BOS) received a €565,000 order for a robotic production line from an Israeli defense-industry customer, set for delivery in Q4 2024. This aligns with BOS' strategic growth plan focusing on the Israeli defense market.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:26 pm

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced four presentations on sotagliflozin at the American College of Cardiology session, highlighting its efficacy in reducing stroke and heart attack risk among patients with type 2 diabetes, CKD, and high CV risk. The FDA approved sotagliflozin in 2023 for reducing cardiovascular death and hospitalization in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:25 pm

ESPR

Esperion Therapeutics Inc's (NASDAQ:ESPR) stock is trading higher after the FDA approved new label expansions for its drugs NEXLETOL and NEXLIZET, based on CLEAR Outcomes data. These expansions include indications for cardiovascular risk reduction and LDL-C lowering in primary and secondary prevention patients. The approvals make over 70 million patients eligible for these treatments. The company also anticipates a final determination from the European Medicines Agency on label expansions in Europe by the second quarter of 2024.

Portfolio Pulse from Vandana Singh

March 25, 2024 | 1:24 pm

BA

DBC

NVDA

PCG

On CNBC's 'Halftime Report Final Trades,' analysts recommended Boeing (BA), PG&E (PCG), Invesco DB Commodity Index Tracking Fund (DBC), and NVIDIA (NVDA). Boeing faces cash outflow concerns due to regulatory scrutiny. PG&E raised its FY24 earnings outlook after better-than-expected Q4 earnings. NVIDIA received a price target increase from UBS and unveiled new products at its GTC event. The stocks showed mixed performance on Friday, with BA and NVDA gaining, while PCG and DBC fell.

Portfolio Pulse from Avi Kapoor

March 25, 2024 | 1:17 pm

TFFP

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced its Phase 2 study of Tacrolimus Inhalation Powder for lung transplant rejection prevention will be presented at the ISHLT 2024 Meeting. The study suggests that this method could offer effective immunosuppression with lower systemic exposure than oral tacrolimus. The presentation will detail the trial's safety, tolerability, efficacy, and pharmacokinetics in patients with significant renal impairment.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:16 pm

KHC

Kraft Heinz has been selected to receive up to $170 million from the U.S. Department of Energy to implement clean energy projects at 10 of its U.S. plants, aiming to reduce carbon emissions by over 99% from 2022 levels. This funding supports Kraft Heinz's goal of achieving net-zero greenhouse gas emissions by 2050. The projects will involve installing various technologies like heat pumps and solar panels, expected to create 500 construction jobs. This initiative is part of Kraft Heinz's broader ESG goals and its commitment to environmental sustainability.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:12 pm

AIM

AIM ImmunoTech announced the publication of a study in the Clinical Cancer Research journal, evaluating its drug Ampligen in the treatment of pancreatic cancer. The findings could have significant implications for the company's drug development pipeline and its position in the oncology market.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:10 pm

AUDC

AudioCodes (AUDC) has partnered with Tata Tele Business Services (TTBS) to integrate voice calling in Microsoft Teams for TTBS's enterprise customers in India, utilizing AudioCodes' SaaS solutions for Microsoft Operator Connect and Direct Routing.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:07 pm